Advert - Voluntary admission by Celgene

• Date posted
  01 February 2017
• Sanction
  Advertisement,
• Case number/s
  AUTH/2831/4/16 - Voluntary admission by Celgene

Celgene made a voluntary admission in relation to the organisation and the materials produced for two meetings arranged to promote Otezla (apremilast) and was ruled in breach of the following clauses of the Code:

Clause 2 - Bringing discredit upon, and reducing confidence in, the pharmaceutical industry.

Clause 4.1 - Failing to include prescribing information.

Clause 4.10 - Failing to include information on adverse events.

Clause 9.1 - Failing to maintain high standards.

Clause 14.1 - Failing to certify, check and sign material in its final form.

Clause 15.2 - Representatives and their manager failing to maintain a high standard of ethical conduct.

Clause 18.1 - Providing an inducement to prescribe or recommend a medicine.

Clause 26.1 - Promoting a prescription only medicine to the public.

The Code of Practice Panel reported Celgene to the Code of Practice Appeal Board. The interim case report is available at www.pmcpa.org.uk.